Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 2,145 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $18.46, for a total value of $39,596.70. Following the sale, the chief financial officer directly owned 216,637 shares of the company’s stock, valued at $3,999,119.02. The trade was a 0.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kyle Piskel also recently made the following trade(s):

• On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $77,220.00.
• On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.50, for a total transaction of $3,174,990.00.
• On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.05, for a total transaction of $3,343.90.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT traded down $0.70 during midday trading on Friday, reaching $15.77. The stock had a trading volume of 4,139,315 shares, compared to its average volume of 1,811,910. The stock has a market capitalization of $2.41 billion, a P/E ratio of -39.42 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 1-year low of $6.26 and a 1-year high of $20.76. The firm’s fifty day simple moving average is $17.03 and its 200-day simple moving average is $15.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 48.73%. The business’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.23) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its holdings in shares of Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Geode Capital Management LLC increased its stake in Adaptive Biotechnologies by 15.6% in the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after acquiring an additional 434,347 shares during the period. Aristotle Atlantic Partners LLC raised its position in Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after purchasing an additional 247,402 shares in the last quarter. Jennison Associates LLC lifted its stake in Adaptive Biotechnologies by 103.9% during the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after purchasing an additional 1,363,181 shares during the period. Finally, Fred Alger Management LLC boosted its holdings in Adaptive Biotechnologies by 6.7% during the third quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock valued at $37,613,000 after purchasing an additional 158,807 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on ADPT shares. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday. BTIG Research raised their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.